Vertex’s Third Cystic Fibrosis Treatment Gets FDA Approval
Vertex Pharmaceuticals Incorporated VRTX announced that the FDA has granted approval to its cystic fibrosis (CF) corrector, tezacaftor (VX-661), in combination with ivacaftor (Kalydeco) under the brand name, Symdekotm. The combo therapy is approved to treat the underlying cause of CF in patients aged 12 years and above with certain mutations in the CF transmembrane conductance regulator gene. This approval marks the company's third treatment for the underlying cause of CF. […]